Boxer Capital Management, LLC
San Diego, CA · CIK 2018299 · 13F filing filed 2026-05-15
SEC-registered investment adviser since 2024 · limited liability company
- Assets managed$578.2m
- Staff19 · 8 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds2 (2 hedge) · $578.2m gross assets
- Websiteboxercap.com
- Form ADV · 2026-05-11SEC adviser record
- Legal entityBOXER CAPITAL MANAGEMENT, LLC (US)
- Kindhedge funds
- Others nearbySan Diego, CA
As an employer
- Offices in1 country
- Private fundshedge 2
$761.7m
reported value
+66.7% vs Q4 2025
54positions
63.3%in top 10
13 new
13 added
3 reduced
4 sold out
vs Q4 2025
Holdings, Q1 2026
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| TANGO THERAPEUTICS INC TNGX | $227.5m29.87% | Unchanged |
| KODIAK SCIENCES INC KOD | $51.9m6.81% | Added +225.0k |
| REVOLUTION MEDICINES INC RVMD | $48.6m6.38% | Added +100.0k |
| KYMERA THERAPEUTICS INC KYMR | $27.4m3.60% | Unchanged |
| CELCUITY INC CELC | $25.7m3.37% | Unchanged |
| SURROZEN INC SRZN | $22.3m2.93% | Added +350.2k |
| ABIVAX SA ABVX | $22.3m2.92% | Added +75.0k |
| TERNS PHARMACEUTICALS INC COM | $19.8m2.60% | Unchanged |
| VAXCYTE INC PCVX | $18.9m2.48% | New |
| CAPRICOR THERAPEUTICS INC CAPR | $17.9m2.35% | Added +265.0k |
| PROTAGONIST THERAPEUTICS INC PTGX | $17.9m2.35% | Unchanged |
| VIR BIOTECHNOLOGY INC VIR | $16.7m2.20% | Added +1.2m |
| CORVUS PHARMACEUTICALS INC CRVS | $16.1m2.11% | New |
| PRAXIS PRECISION MEDICINES I PRAX | $15.0m1.97% | Unchanged |
| PTC THERAPEUTICS INC PTCT | $13.6m1.79% | Unchanged |
| PRECIGEN INC PGEN | $13.5m1.78% | Added +2.1m |
| DEFINIUM THERAPEUTICS INC DFTX | $11.3m1.49% | New |
| AMYLYX PHARMACEUTICALS INC AMLX | $11.1m1.46% | Unchanged |
| UNIQURE NV QURE | $10.8m1.42% | Added +372.0k |
| OPUS GENETICS INC IRD | $10.2m1.34% | New |
| CORCEPT THERAPEUTICS INC CORT | $10.1m1.32% | New |
| UROGEN PHARMA LTD URGN | $9.0m1.18% | Unchanged |
| REPLIMUNE GROUP INC REPL | $9.0m1.18% | Added +425.0k |
| COGENT BIOSCIENCES INC COGT | $8.7m1.14% | Unchanged |
| PALISADE BIO INC PALI | $8.4m1.10% | Unchanged |
| CRESCENT BIOPHARMA INC. COM | $8.3m1.09% | New |
| SOLENO THERAPEUTICS INC SLNO | $6.7m0.88% | New |
| ALLOGENE THERAPEUTICS INC ALLO | $6.6m0.87% | New |
| CYTOKINETICS INC CYTK | $6.6m0.87% | Unchanged |
| CONTINEUM THERAPEUTICS INC CTNM | $6.5m0.85% | Unchanged |
| APOGEE THERAPEUTICS INC COM | $5.9m0.77% | Unchanged |
| RELMADA THERAPEUTICS INC RLMD | $5.9m0.77% | New |
| ZURA BIO LTD ZURA | $5.4m0.70% | Added +850.0k |
| MOONLAKE IMMUNOTHERAPEUTICS MLTX | $5.1m0.67% | Unchanged |
| AVALO THERAPEUTICS INC AVTX | $4.5m0.59% | Added +25.0k |
| INOVIO PHARMACEUTICALS INC INO | $4.1m0.54% | Reduced -50.0k |
| STRUCTURE THERAPEUTICS INC GPCR | $3.6m0.47% | Unchanged |
| SAREPTA THERAPEUTICS INC SRPT | $3.3m0.43% | Unchanged |
| CYBIN INC COM NEW | $3.1m0.40% | Reduced -75.0k |
| OCULAR THERAPEUTIX INC OCUL | $3.0m0.39% | New |
| AN2 THERAPEUTICS INC ANTX | $2.6m0.34% | New |
| CLENE INC CLNN | $2.4m0.31% | Added +277.8k |
| ORIC PHARMACEUTICALS INC ORIC | $2.2m0.29% | New |
| SOLID BIOSCIENCES INC SLDB | $2.2m0.28% | Unchanged |
| INVIVYD INC IVVD | $1.9m0.26% | Unchanged |
| LB PHARMACEUTICALS INC LBRX | $1.7m0.23% | Unchanged |
| KARYOPHARM THERAPEUTICS INC KPTI | $1.7m0.22% | Added +50.0k |
| NURIX THERAPEUTICS INC NRIX | $1.6m0.20% | Unchanged |
| UPSTREAM BIO INC UPB | $1.4m0.18% | Unchanged |
| MILESTONE PHARMACEUTICALS IN MIST | $793.3k0.10% | Unchanged |
| PEPGEN INC PEPG | $483.0k0.06% | Reduced -101.0k |
| KALVISTA PHARMACEUTICALS INC KALV | $410.7k0.05% | Unchanged |
| REGENXBIO INC RGNX | $125.7k0.02% | New |
| SURROZEN INC *W EXP 08/01/203 | $1.1k0.00% | Unchanged |
Sold out since Q4 2025
| Security | Value then |
|---|---|
| CIDARA THERAPEUTICS INC CDTX | $11.7m53.0k shares |
| MIND MEDICINE MINDMED INC | $8.0m598.5k shares |
| CRESCENT BIOPHARMA INC. CBIO | $5.4m453.7k shares |
| NUVATION BIO INC NUVB.WS | $88.0k266.7k shares |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| Q32 BIO INC QTTB · 13G · filed 2026-07-10 | 13.3%≈ $40.1m |
| SURROZEN INC SRZN · 13G · filed 2026-10-07 | 11.6%≈ $35.3m |